These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 33971321)

  • 21. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
    Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

  • 26. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
    Nokin MJ; Mira A; Patrucco E; Ricciuti B; Cousin S; Soubeyran I; San José S; Peirone S; Caizzi L; Vietti Michelina S; Bourdon A; Wang X; Alvarez-Villanueva D; Martínez-Iniesta M; Vidal A; Rodrigues T; García-Macías C; Awad MM; Nadal E; Villanueva A; Italiano A; Cereda M; Santamaría D; Ambrogio C
    Nat Commun; 2024 Aug; 15(1):7554. PubMed ID: 39215000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
    Mohanty A; Nam A; Srivastava S; Jones J; Lomenick B; Singhal SS; Guo L; Cho H; Li A; Behal A; Mirzapoiazova T; Massarelli E; Koczywas M; Arvanitis LD; Walser T; Villaflor V; Hamilton S; Mambetsariev I; Sattler M; Nasser MW; Jain M; Batra SK; Soldi R; Sharma S; Fakih M; Mohanty SK; Mainan A; Wu X; Chen Y; He Y; Chou TF; Roy S; Orban J; Kulkarni P; Salgia R
    Sci Adv; 2023 Oct; 9(41):eade3816. PubMed ID: 37831779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ULK1/2 and KRAS
    Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M
    Elife; 2024 Aug; 13():. PubMed ID: 39213022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting
    Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
    Front Oncol; 2022; 12():796832. PubMed ID: 35251972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to KRAS
    Blaquier JB; Cardona AF; Recondo G
    Front Oncol; 2021; 11():787585. PubMed ID: 35004309
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of
    Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
    Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
    Brazel D; Nagasaka M
    Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS
    Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.